-
Innovation Ranking
NewInnovation Ranking – ADT Inc
ADT Inc (ADT) is a provider of monitored security, interactive home, and business automation services. The company offers home and business security systems and services for video surveillance, access control, temperature monitoring, flood monitoring, fire and smoke, carbon monoxide monitoring, and other environmental conditions and hazards. It also offers personal emergency response system products and services, maintenance, and installation services. ADT serves owners of single-family homes; retail businesses; medical offices; financial institutions; food and beverage service providers; and professional service...
-
Thematic Analysis
NewGlobal Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Breast Cancer Drug Details: Enzalutamide (Xtandi) is a phenylimidazolidine derivative,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Refractory Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Refractory Multiple Myeloma Drug Details: Enzalutamide (Xtandi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Relapsed Multiple Myeloma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Relapsed Multiple Myeloma Drug Details: Enzalutamide (Xtandi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Epithelial Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Epithelial Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Epithelial Ovarian Cancer Drug Details: Enzalutamide (Xtandi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Fallopian Tube Cancer Drug Details: Enzalutamide (Xtandi) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Enzalutamide in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Enzalutamide in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Enzalutamide in Peritoneal Cancer Drug Details: Enzalutamide (Xtandi) is a phenylimidazolidine...